Senior ML engineers working biotech AI roles in the Kendall Square–Longwood Medical Area corridor earn a 28% to 32% premium over comparable general software engineering roles in Greater Boston — a gap that Massachusetts pay transparency law is, for the first time, converting from rumor into posted range. Nine months after the Massachusetts Wage Transparency Act took effect on October 29, 2025, ENTRA's Q2 2026 Job Signal Index counted 340-plus active AI and ML postings across Greater Boston, with 54% carrying a visible salary range, up from 41% in Q1 2026. That 13-point quarter-over-quarter gain is the fastest single-quarter disclosure acceleration ENTRA has recorded in any US metro market since Colorado's EPEWA went into force in 2021. What the disclosed numbers show: Moderna is hiring ML engineers at $170K–$220K base, Vertex Pharmaceuticals at $175K–$225K, and the Broad Institute at $155K–$195K — bands that, six months ago, candidates had to reach an offer to see.
The Law That Changed the Posting
Massachusetts Governor Maura Healey signed An Act Relative to Salary Range Transparency — introduced as Senate bill S.2897 — on July 31, 2024. The law took effect October 29, 2025. Any employer with 25 or more employees posting a Massachusetts-based role must include the pay range that the employer "reasonably and in good faith expects to pay" at the time of posting. The mandate applies to remote roles where the employee's primary place of work is Massachusetts, closing the loophole that let multi-state employers post national roles without disclosure.
Enforcement sits with the Massachusetts Attorney General's Civil Rights Division. For the law's first two years — through October 29, 2027 — employers receive a two-business-day cure period to fix violations after receiving notice, before fines apply. That grace window was designed to accommodate honest implementation lag; it has also given life sciences employers a rational basis for measured compliance. The AG's office has exclusive authority and there is no private right of action.
The result in year one: partial compliance, concentrated at the companies largest enough to have built compensation architecture before the mandate landed. ENTRA's Q2 2026 audit of biotech and life sciences employers in Greater Boston finds a compliance rate of 52% to 58% — lower than general tech, where the same methodology yields roughly 71%. Biotech lags for structural reasons covered in the next section. The trend line matters more than the snapshot: the Q1-to-Q2 2026 jump from 41% to 54% suggests the cure window is doing its job, and that the AG's Civil Rights Division does not need to issue formal citations to shift behavior.
Kendall Square: What the Bands Now Show
The Kendall Square corridor — roughly bounded by Main Street to the east, the MIT campus to the west, and the Charles River to the south — contains the densest concentration of biotech-AI hiring per square mile of any US life sciences cluster. Six hundred-plus life sciences companies operate within a single square mile of the square. The pay transparency law now makes that density legible in compensation terms for the first time.
Broad Institute (nonprofit): ML Engineer base, $155K–$195K. The Broad, a joint Harvard-MIT research institution with a budget north of $1 billion annually, posts ranges that reflect its nonprofit status: bands sit 10% to 15% below for-profit pharma peers on base but are competitive when total compensation includes fellowship supplements and the research environment premium that draws computational biologists away from industry. Government grants constrain band width; the Broad cannot offer public pharma equity structures.
Moderna: AI team ML Engineer, $170K–$220K base. Moderna's AI and digital science function, rebuilt after 2024's restructuring, is now hiring aggressively across its Cambridge headquarters. The disclosed band reflects the company's post-mRNA commercial success and its intention to use AI as a core platform for vaccine and therapeutic design beyond COVID. Equity at Moderna is NASDAQ-listed MRNA stock, making the total compensation picture more legible than pre-IPO biotech peers.
Vertex Pharmaceuticals: Senior ML Engineer, $175K–$225K base. Vertex sits at the top of the Kendall Square base-salary register for ML roles. Its cystic fibrosis franchise generates free cash flow at a scale that funds above-market AI compensation; the company has no debt and a $25 billion-plus cash position as of Q2 2026. The $175K–$225K band does not include Vertex's performance bonus structure, which adds 15% to 20% at target for senior individual contributors.
MIT Lincoln Laboratory: ML Engineer, $145K–$185K base. Lincoln Lab operates as a federally funded research and development center under Department of Defense contract. Government contractor compensation structures cap total compensation growth in ways commercial peers are not subject to; Lincoln Lab's base ranges reflect DoD salary guidelines rather than pharma market rates. The trade: job security, access to classified and sensitive research environments, and benefits packages that include federal-equivalent retirement matching.
Longwood Medical Area: Dana-Farber Cancer Institute and Mass General Brigham's AI Center post ML roles at $140K–$180K base. The Longwood cluster, anchored by Harvard Medical School and twelve affiliated hospitals within a half-mile, competes for AI talent on mission and research access rather than total compensation. Dana-Farber's AI program, focused on oncology data and clinical trial optimization, draws ML engineers from quantitative finance and Big Tech who want domain proximity to clinical outcomes. Mass General Brigham's AI Center is newer; it is building toward parity with academic medical center peers that have run AI programs for longer. Both institutions are now disclosing in compliance with S.2897.
For comparison anchors, Big Tech's Boston footprints post at higher bands: Microsoft's New England R&D operation, operating out of its Cambridge office, shows $195K–$280K base for senior AI engineering roles, per postings audited by ENTRA in Q2 2026. Amazon AWS Boston runs $185K–$270K across ML and AI engineering levels. Those Big Tech ranges represent the ceiling against which biotech employers must compete for talent with dual domain expertise.
Total compensation for a senior AI and ML engineer at a public biotech in Boston — base plus equity priced at 2026 public market levels, assuming a four-year vest — sits in the $230K–$310K range per ENTRA's Q2 2026 Salary Survey. That positions Boston biotech AI below Bay Area biotech-AI total comp by approximately 18% to 22%, but above Boston general software engineering by 28% to 32%. The biotech-AI premium is real, and the transparency law is making it visible.
Why Biotech Discloses Less Than Big Tech
The 52%-to-58% disclosure rate in life sciences Boston versus 71% in general tech reflects three distinct structural factors, not employer bad faith.
Compensation architecture complexity. Biotech total compensation for AI roles frequently includes milestone bonuses tied to regulatory submissions and drug approval events, equity in multiple clinical-stage entities (at companies with pipeline assets), and retention grants that fall outside standard band frameworks. Posting a "pay range" is technically straightforward when compensation is base plus RSU; it requires legal and HR judgment calls when the package includes a bonus that pays out if a Phase III trial hits a primary endpoint. S.2897's definition of "pay range" — the salary or hourly wage the employer "reasonably and in good faith expects to pay" — does not resolve how to treat contingent clinical milestone compensation. Employers are waiting for AG guidance.
Government contractor constraints. MIT Lincoln Laboratory, Draper Laboratory, and several defense AI contractors operating in the Boston metro cannot disclose pay ranges that reference classified position classifications or compensation tied to security clearance levels. DoD salary structure intersects with Massachusetts disclosure requirements in ways that the AG's guidance, published at the law's effective date, acknowledges but does not fully resolve.
Nonprofit band governance. Institutions like the Broad Institute, Dana-Farber, and Mass General Brigham govern compensation through board-approved salary structures that require trustee action to modify. The two-year cure window has given those institutions time to move band disclosures through governance cycles that would have missed the initial October 2025 deadline.
The demand context makes the compliance lag consequential. AI-tagged postings in Greater Boston's life sciences sector grew 74% year over year per ENTRA's Q2 2026 Job Signal Index — the fastest growth rate among the six US markets ENTRA covers in the biotech-AI category. Candidates who cannot see salary bands before applying convert at lower rates. At current posting volumes, a 52% disclosure rate means roughly 160 of the 340-plus active postings in July 2026 still do not show compensation. That is 160 talent conversations where the first transparency moment is an offer — after reference checks, technical screens, and hiring manager interviews have already consumed candidate attention.
What the Housing Math Adds
The 28%-to-32% biotech AI premium over general Boston tech comp exists in a market where housing is substantially cheaper than the San Francisco Bay Area. A two-bedroom apartment in Boston proper runs $2,700–$3,400 per month; Cambridge-side units carry a 15%-to-20% premium to that range, particularly in the Kendall Square zip code. The equivalent in San Francisco is 38% higher. For a senior ML engineer at Moderna considering a role in Cambridge versus a role at Genentech in South San Francisco, the base salary delta is partially offset by the housing cost differential — a math that Massachusetts transparency law is now making possible to run with real numbers, not recruiter estimates.
That cost-of-living adjustment, visible only when salary bands are posted, is an underappreciated recruiting tool for Boston biotech employers competing for talent that would otherwise default to Bay Area AI labs.
What Comes Next
Three developments will determine how the Kendall Square–Longwood corridor's disclosure rate moves between now and the October 2027 end of the cure period.
Massachusetts AG enforcement posture. The Civil Rights Division has not yet publicly moved against a biotech employer on S.2897 violations. The two-year cure period is designed to avoid enforcement confrontation before employers have had time to build compliance infrastructure. That period ends October 29, 2027. Between now and then, expect the AG to publish updated guidance on milestone-bonus compensation and government contractor exemptions — the two areas where employer ambiguity is most defensible. ENTRA expects the Q3 2026 guidance update to accelerate disclosure in both categories.
Federal Salary Transparency Act. H.R. 2007 in the 119th Congress would amend the Fair Labor Standards Act to require all US employers to disclose wage ranges in employment postings, eliminating the state-by-state patchwork that currently lets multi-state biotech companies disclose in Massachusetts but not in Georgia or Texas sites. The bill has not cleared committee. It has been introduced in prior sessions without passage. What has changed: the state adoption rate is now sufficient that a federal standard would codify existing practice for most large employers rather than impose a new burden, which shifts the political economy of opposition.
Disclosure rate trajectory. At the Q1-to-Q2 2026 pace — 41% to 54%, a 13-point single-quarter gain — Greater Boston's biotech AI market clears 67% disclosure by Q4 2026 and approaches the 80% threshold that ENTRA has documented as the inflection point where candidate conversion rates stabilize. That math assumes the AG's guidance update lands before Q3 2026 ends. If it slips to Q4, the 80% threshold moves to Q1 2027.
The 28%-to-32% biotech AI premium in Boston is a structural feature of a market where ML engineers must understand protein folding pipelines, clinical trial data architectures, or molecular dynamics simulations to do the job. Massachusetts S.2897 did not create that premium; it made it legible. The employers disclosing it now are not being generous. They are competing.
ENTRA Q2 2026 Job Signal Index: Greater Boston AI/ML postings audited April–June 2026; 340-plus active postings as of July 2026. Disclosure rate methodology: ENTRA audits live postings for visible pay range before application, consistent with S.2897's definition of "pay range." Biotech AI premium (+28% to +32%) calculated against ENTRA's Greater Boston General Software Engineering Salary Benchmark, Q2 2026. Individual employer salary bands (Broad Institute, Moderna, Vertex, MIT Lincoln Laboratory, Dana-Farber, Mass General Brigham) drawn from postings audited by ENTRA in Q2 2026 and cross-referenced against Glassdoor and Levels.fyi self-reported data; individual employers did not confirm. Big Tech Boston bands (Microsoft New England R&D, Amazon AWS Boston) per ENTRA Q2 2026 posting audit. Total compensation for senior biotech AI engineer ($230K–$310K) per ENTRA Q2 2026 Salary Survey, base plus equity at public biotech 2026 market rates. Boston 2BR rent ($2,700–$3,400) per ENTRA Q2 2026 housing index; Cambridge-side premium per market data. SF equivalency (-38%) per ENTRA cross-metro housing index. YoY AI-tagged life sciences posting growth (+74%) per ENTRA Q2 2026 Job Signal Index, Greater Boston filter. Massachusetts Wage Transparency Act (An Act Relative to Salary Range Transparency): signed July 31, 2024; effective October 29, 2025; enforcement authority Massachusetts AG Civil Rights Division; cure period through October 29, 2027. H.R. 2007 Salary Transparency Act status per Congress.gov, 119th Congress.
Global Career PlatformFind AI talent. Find your next role.
Booking is hotels. · Airbnb is apartments. · ENTRA is global careers.